Novo subpoenaed by U.S. attorney for manufacturing issues; AbbVie exec scolds Canada over patents;

@FiercePharma: Top-read in FiercePharma Thurs: Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. To get it weekly, subscribe. Subscribe | Follow @CarlyHFierce

> Novo Nordisk ($NVO) reported today that it has been subpoenaed by the U.S. Attorney in Massachusetts over manufacturing issues at a plant in Denmark. Release

> The head of AbbVie's ($ABBV) Canada operations said the country is unlikely to get much R&D investment as long as its patents on drugs is more restrictive than other Western countries. Story

> Jordan's Hikma reports that it has gotten a warning letter from the FDA for a plant in Portugal. Story

Medical Device News

@FierceMedDev: New microscope offers 3D cellular images that are fast, detailed and low toxicity. More | Follow @FierceMedDev

@VarunSaxena2: Bard Q3 earnings up 41% as it focuses on Lutonix launch. Story | Follow @VarunSaxena2

@EmilyWFierce: $JNJ scores victory in first metal-on-metal hip implant case to go to trial. Article | Follow @EmilyWFierce

@MichaelGFierce: Encapsulated #Alzheimers, #Parkinsons-treating growth factors implanted directly in the brain. More from FierceDrugDelivery | Follow @MichaelGFierce

> Apple kicks med tech app developers out of the iCloud. Item

> Edwards profit up 23%, but increased TAVR competition looming. Story

Biotech News

@FierceBiotech: $GSK cozies up to Five Prime for respiratory R&D. More | Follow @FierceBiotech

@JohnCFierce: Baxter gets FDA OK for hemophilia A drug -- Obizur. News | Follow @JohnCFierce

@DamianFierce: $AZN's olaparib will trade as Lynparza, which sounds like a nice lady. | Follow @DamianFierce

@EmilyMFierce: Researchers will test blood of Ebola survivors to use as a short-term treatment option. Story | Follow @EmilyMFierce

> AstraZeneca gets some EU encouragement for its $2B cancer hopeful. More

> Shire CFO to exit in wake of failed AbbVie deal. Chutes & Ladders

> NPS Pharma will have to wait another three months for an FDA OK. News

And Finally... Your milk choice may impact your vitamin D levels. More (sub. req.)

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.